📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-21 20:04
646 analysed today
646
Today
133,535
All-time analysed
40,118
Positive
6,284
Negative
79,315
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Lords Mark Targets ₹2,000+ Cr Revenue by FY28; Renewable Order Book at ₹3,000 Cr
Lords Mark Industries released its Q1 FY27 investor call transcript following its recent reverse-merger listing. The company reported Q1 topline of approximately ₹280 crore and bottomline of ₹32 crore, with 55% revenue contributed by IVD & Medtech and 45% by Renewable Energy. Management disclosed an active renewable energy order book of around ₹3,000 crore and guided for over ₹2,000 crore in annual revenue with 10-11% PAT margins by FY28. To comply with the 75% minimum public shareholding rule, the company is evaluating an OFS, rights issue, or QIP to dilute its current ~80% promoter holding.
Confidence: HIGH
What changedManagement conducted an investor call detailing segment margins, forward revenue guidance (₹2,000+ crore by FY28), product pipeline launches, and promoter stake dilution plans.
Why it mattersProvides operational clarity post reverse-merger listing, highlighting a transition toward higher-margin Medtech products (20% EBITDA) alongside a sizeable ₹3,000 crore renewable energy order book.
Renewable Order Book: ₹3000 crFY28 Revenue Guidance: > ₹2000 crQ1 Revenue: ~₹280 crQ1 PAT: ~₹32 crMedtech EBITDA Margin: around 20%Renewable EBITDA Margin: around 11%
📅 Short termNeutral to mildly positive as the market assesses the feasibility of the FY28 targets and awaits details on the upcoming promoter dilution route (OFS/Rights/QIP).
📈 Long termStructural growth hinges on successful commercialization and scale-up of indigenous medical technologies (dialysis, sickle cell, cancer diagnostics) and timely execution of government renewable contracts.
⚠ Risk flags
- Dilution overhang from required reduction in promoter holding to 75%
- Regulatory approval risk for new diagnostic products with ICMR/CDSCO
- Government client concentration and execution delays in renewable energy projects
Key Highlights
Renewable energy order book stands at approximately ₹3,000 crore
Targets crossing ₹2,000+ crore revenue with 10-11% PAT margin by FY28
Q1 FY27 revenue mix was 55% IVD & Medtech (20% EBITDA margin) and 45% Renewable Energy (11% EBITDA margin)
Planning equity dilution via OFS/rights/QIP to reduce promoter holding from ~80% to 75%
Dialysis machine commercial production started with Bharat Electronics (BEL) as manufacturing partner
👀 What to Watch
Track commercial launch timelines and regulatory approvals (ICMR/CDSCO) for sickle cell and oncology diagnostic products expected in Q4 FY27, along with the execution pace of the ₹3,000 crore renewable order book.
Infomerics Upgrades Lords Mark's Rating to IVR A-/Stable; Facilities Enhanced to ₹260.37 Cr
Infomerics Valuation and Rating Ltd has upgraded the credit ratings for Lord's Mark Industries Limited's bank loan facilities. The long-term rating has been upgraded to IVR A-/Stable, and the short-term rating has been revised upward to IVR A2+. Additionally, the total quantum of rated bank facilities has been enhanced from ₹191.03 crore to ₹260.37 crore. The rating is valid for one year through August 16, 2027.
Confidence: HIGH
What changedCredit rating agency Infomerics upgraded the company's bank facilities to IVR A-/Stable (Long Term) and IVR A2+ (Short Term), while increasing the coverage quantum to ₹260.37 crore.
Why it mattersA credit rating upgrade signals improved financial health and debt-servicing capability, which can lower borrowing costs and improve credit access from commercial banks.
Enhanced Rated Facilities: Rs. 260.37 CrorePrevious Rated Facilities: Rs. 191.03 CroreLong-Term Rating: IVR A- / StableShort-Term Rating: IVR A2+Rated Facilities vs Total Debt: ~95%
📅 Short termPositive for market sentiment regarding solvency and access to short-term working capital lines.
📈 Long termEnhances long-term debt profile and reduces credit risk perception, potentially lowering the blended cost of debt over coming quarters.
⚠ Risk flags
- Subject to regular surveillance and compliance with monthly no-default declarations
Key Highlights
Long-term bank facility rating upgraded to IVR A-/Stable by Infomerics
Short-term bank facility rating upgraded to IVR A2+
Total rated bank facilities enhanced to ₹260.37 crore from ₹191.03 crore
Rating review took into account performance for FY25 (Audited) and FY26 (Provisional)
👀 What to Watch
Track whether the credit upgrade leads to lower borrowing costs on the company's ₹274 crore debt and observe working capital utilization in upcoming quarterly filings.
Lords Mark Targets ₹1,550 Cr Revenue in FY27; Announces Demerger and Major Healthcare Expansion
Lords Mark Industries has issued aggressive FY2027 guidance, targeting consolidated revenue of ₹1,550 crore (up from ₹602 crore in FY26) and PAT of ₹178 crore. The company is undergoing a major strategic shift, including the demerger of its Renewable Energy & LED division into a 60% subsidiary by March 2027. Expansion plans include establishing 50 dialysis centers, 2 oncology hospitals (70 beds each), and international pathology labs in the UK and Switzerland by early 2027. To fund the oncology pilot, the company plans a ₹200 crore debt raise in December 2026.
Confidence: HIGH
What changedThe company is pivoting from a consulting and energy-heavy model to a diversified healthcare delivery platform with international diagnostic operations and a planned corporate restructuring.
Why it mattersThe guidance suggests a massive scale-up in operations (2.5x revenue growth) and a shift toward recurring service-based revenue in healthcare, which typically commands higher valuation multiples than consulting or equipment sales.
FY27 Revenue Guidance: ₹1,550 crFY27 PAT Guidance: ₹178 crProposed Debt Raise: ₹200 crGuidance vs FY26 Revenue: 257%Dialysis Centers Target: 50Oncology Hospital Beds: 140
📅 Short termThe market is likely to react positively to the high growth guidance and the value-unlocking potential of the demerger, though the ₹200 cr debt requirement will be a key watchpoint.
📈 Long termIf executed, the transition into oncology, CAR-T therapy, and international diagnostics could structurally re-rate the company from a consulting firm to a healthcare major.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High execution risk across multiple simultaneous new business verticals
- Significant debt addition (₹200 cr) relative to current market cap
- Historical price volatility and negative P/E ratio
Key Highlights
FY2027 revenue guidance of ₹1,550 crore represents a 157% increase over FY26 revenue of ₹602 crore
Proposed ₹200 crore debt raise in December 2026 to fund two 70-bed oncology hospitals in Vapi and Solapur
Demerger of Renewable Energy & LED business into Lords Shakti Power Ltd to be filed by March 2027
Targeting 50 dialysis centers across India by March 2027 using an asset-light rented-premises model
PAT guidance of ₹178 crore for FY27 implies a 50% growth and a 200bps margin expansion to 11.4%
👀 What to Watch
Monitor the successful closure of the ₹200 crore debt raise in December 2026 and the regulatory filing of the demerger scheme by March 2027 as key execution milestones.
₹1,550 Cr Revenue Guidance for FY27 and Demerger of Energy Business
Lords Mark Industries has announced an aggressive growth roadmap for FY2027, targeting revenue of ₹1,550 crore (up from ₹602 crore in FY2026) and a PAT of ₹178 crore. The company plans to demerge its Renewable Energy & LED division into a 60%-owned subsidiary, Lords Shakti Power, by March 2027 to unlock healthcare valuation. Major healthcare expansions include 50 dialysis centers, two 70-bed oncology hospitals funded by a ₹200 crore debt raise, and international pathology labs in the UK and Switzerland. Additionally, the company has secured ICMR approval for its OneDNA genomic platform and a manufacturing license for its Biomescan AI diagnostic software.
Confidence: HIGH
What changedThe company is transitioning from a diversified conglomerate to a focused healthcare and diagnostics platform while spinning off its energy business into a separate entity.
Why it mattersThe guidance suggests a massive scale-up in operations and a shift toward recurring service-based revenue (dialysis, hospitals) rather than just equipment sales. The demerger is intended to allow the market to value the healthcare business independently of the capital-intensive energy division.
FY27 Revenue Guidance: ₹1,550 crFY27 PAT Guidance: ₹178 crProposed Debt Raise: ₹200 crGuidance vs FY26 Revenue: 257.4%Dialysis Centers Target: 50
📅 Short termThe ambitious guidance and demerger news are likely to be viewed positively by the market, though the stock's historical volatility remains a factor.
📈 Long termIf executed, the shift into oncology, CAR-T therapy, and international diagnostics could structurally re-rate the company from a consulting/trading firm to a specialized healthcare provider.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High execution risk across multiple simultaneous new verticals
- Significant debt addition (₹200 cr) relative to current market cap
- Historical stock price performance shows extreme volatility
Key Highlights
FY2027 revenue guidance set at ₹1,550 crore, implying a ~157% increase over FY2026 revenue of ₹602 crore
Proposed demerger of Energy/LED division into Lords Shakti Power Limited to be filed by March 2027
Planned ₹200 crore debt raise in December 2026 to fund two 70-bed oncology hospitals in Vapi and Solapur
Targeting 50 dialysis centers across India by March 2027 using an asset-light rented premises model
Expansion into UK and Switzerland with pathology labs, with UK operations starting January 2027
👀 What to Watch
Monitor the successful closure of the ₹200 crore debt raise in December 2026 and the formal filing of the demerger scheme by March 2027. Investors should also track the commencement of the UK pathology operations in January 2027 as a test of international scalability.
₹32.16 Cr Standalone PAT in Q1 FY27; Revenue Declines 36% Sequentially
Lords Mark Industries reported a standalone net profit of ₹32.16 crore for the quarter ended June 30, 2026, down 22% from ₹41.22 crore in the previous quarter (Q4 FY26). Revenue from operations stood at ₹280.36 crore, a sequential decline of 36.6% compared to ₹441.98 crore in March 2026. The company maintained a healthy standalone net profit margin of 11.5%. This is the first full quarter following the amalgamation with Kratos Energy & Infrastructure Limited, making year-on-year comparisons with June 2025 (zero revenue) less meaningful.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, reflecting the operational scale of the entity post-amalgamation with Kratos Energy.
Why it mattersThe results establish a post-merger performance baseline; while sequential revenue dropped, the company remains profitable with a significant asset base of ₹1,380 crore.
Standalone Revenue (Q1 FY27): ₹280.36 CrStandalone PAT (Q1 FY27): ₹32.16 CrQoQ Revenue Growth: -36.6%Short-term Loans & Advances: ₹307.96 CrTrade Receivables: ₹394.75 Cr
📅 Short termThe sequential decline in revenue and profit may lead to cautious sentiment in the short term, despite the absolute profitability.
📈 Long termThe long-term outlook depends on the company's ability to stabilize revenue post-merger and manage its working capital, particularly its high receivables and loans.
⚠ Risk flags
- Significant sequential revenue decline of 36.6%
- High trade receivables at ₹394.75 crore
- Sharp increase in short-term loans and advances to ₹307.96 crore
Key Highlights
Standalone revenue from operations reached ₹280.36 crore in Q1 FY27.
Standalone net profit for the quarter was ₹32.16 crore with an EPS of ₹0.75.
Trade receivables decreased by ₹167.25 crore, ending at ₹394.75 crore compared to ₹562.00 crore in March 2026.
Short-term loans and advances surged significantly to ₹307.96 crore from ₹66.97 crore in the previous quarter.
Consolidated net profit for the quarter stood slightly higher at ₹33.18 crore.
👀 What to Watch
Investors should monitor the recovery of trade receivables and the specific deployment of the ₹307.96 crore in short-term loans and advances, as these impact the company's liquidity profile.
Lords Mark Industries Approves Q1 Results, 5-Year Auditor Term, and Sets Sept 30 AGM
Lords Mark Industries held a board meeting on August 13, 2026, approving the unaudited financial results for the quarter ended June 30, 2026. The board recommended the appointment of M/s Sanjeev S. Gupta & Associates as Statutory Auditors for a five-year term and approved a strategic growth roadmap for FY 2026-27. The 46th Annual General Meeting (AGM) is scheduled for September 30, 2026, with a record date of September 23, 2026. Additionally, the board noted the resignation of the Company Secretary and authorized the CMD to pursue M&A and restructuring activities.
Confidence: HIGH
What changedThe company has refreshed its entire audit panel (Statutory, Internal, Cost, and Secretarial) and formalized its strategic roadmap for FY 2026-27.
Why it mattersThe appointment of auditors for a 5-year term provides governance stability, while the M&A authorization signals intent for inorganic growth or corporate restructuring, which is critical given the stock's recent 99% price decline.
AGM Date: September 30, 2026Record Date: September 23, 2026Statutory Auditor Term: 5 yearsInternal Auditor Term: 3 yearsTTM Revenue: ₹601 Cr
📅 Short termThe market will focus on the specific Q1 earnings figures and the transition of the Company Secretary, who departs on August 20, 2026.
📈 Long termThe 5-year auditor term and M&A authorization suggest a focus on structural stability and expansion, though the company must overcome significant historical price erosion.
⚠ Risk flags
- Resignation of Company Secretary & Compliance Officer
- Significant historical price volatility (-99.3% in 6 months)
- Restructuring of Kratos Energy Infrastructure Limited indicates potential underlying business stress
Key Highlights
Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Recommended appointment of Statutory Auditors for a 5-year term from the 46th AGM to the 51st AGM
Scheduled the 46th Annual General Meeting for September 30, 2026, via video conferencing
Set September 23, 2026, as the record date for determining shareholder eligibility for the AGM
Authorized CMD Sachidanand Upadhyay to execute M&A, mergers, and restructuring of Kratos Energy Infrastructure Limited
👀 What to Watch
Investors should review the detailed Q1 financial results once released to assess if the company is maintaining its TTM revenue of ₹601 Cr. Monitor for any specific M&A announcements following the broad authorization granted to the CMD.
Lords Mark Receives India's First SaMD Manufacturing License for Biomescan Analytics Platform
Lords Mark Industries has become the first company in India to receive a manufacturing license for an In Vitro Diagnostic Software (SaMD) under the Medical Devices Rules, 2017. The license covers its Biomescan Analytics Platform, which uses metagenome sequencing for gut microbiome profiling and preventive healthcare. This regulatory milestone allows the company to commercialize its genomics-based wellness solutions through a planned nationwide network of Health & Wellness Centres. Given the company's rapid revenue growth from Rs 0 in June 2025 to Rs 602 Cr in FY26, this expansion into high-tech diagnostics marks a significant business evolution.
Confidence: HIGH
What changedThe company has transitioned from a developer to a licensed manufacturer of medical diagnostic software, securing a first-mover advantage in the Indian gut microbiome market.
Why it mattersThis license validates the company's proprietary technology and enables the commercial rollout of a new high-margin healthcare vertical, diversifying its revenue stream beyond consulting services.
TTM Revenue: Rs 601 CrTTM PAT: Rs 53 CrPromoter Holding: 79.84%12-Month Price Return: -81.2%Operating Profit Margin (FY26): 14.0%
📅 Short termThe announcement is likely to be viewed positively as a major regulatory win, though the stock has shown extreme volatility recently.
📈 Long termIf successfully scaled through the planned wellness centers, this platform could pivot the company into a specialized healthcare technology player, though execution risks remain high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Extreme historical stock price volatility (-99% in 6 months)
- Execution risk in setting up a physical nationwide wellness network
- High debt levels relative to historical earnings (Rs 274 Cr)
Key Highlights
First and only company in India to receive a manufacturing license for SaMD for gut microbiome analytics.
License granted under the Medical Devices Rules, 2017, for preventive healthcare and early health risk assessment.
Company reported a massive revenue jump to Rs 601 Cr (TTM) from near-zero levels in early 2025.
Strategic plan to establish a nationwide network of Health & Wellness Centres in collaboration with hospitals.
Promoter holding remains high at 79.84% as of June 2026.
👀 What to Watch
Monitor the execution timeline for the proposed nationwide network of Health & Wellness Centres and the subsequent impact on service-based revenue margins in upcoming quarterly results.
Lords Mark Industries to meet 25% MPS mandate via Promoter OFS and Public Rights Issue
Lords Mark Industries has approved a two-step corporate restructuring plan to comply with the 25% Minimum Public Shareholding (MPS) mandate. The current promoter holding stands at 79.84%, requiring a dilution of approximately 4.84% to meet SEBI norms. The plan involves an Offer for Sale (OFS) by the promoter group and a Rights Issue restricted to public shareholders. Nuvama Wealth Management has been appointed as the advisor to manage this capital restructuring.
Confidence: HIGH
What changedThe company has transitioned from non-compliance planning to an active execution phase for meeting SEBI's Minimum Public Shareholding requirements through a formal restructuring scheme.
Why it mattersCompliance with the 25% MPS rule is mandatory for continued listing; the chosen method (Rights Issue) will also likely infuse fresh capital into the company, which reported a TTM revenue of Rs 601 Cr.
Current Promoter Holding: 79.84%MPS Mandate: 25.00%TTM Revenue: Rs 601 CrTTM Net Profit: Rs 53 Cr
📅 Short termThe stock may experience volatility as the market reacts to the potential supply of shares from the Promoter OFS and the terms of the Rights Issue.
📈 Long termSuccessful compliance will improve the stock's liquidity and regulatory standing, though the company's negative market cap and net worth context remain significant structural concerns.
⚠ Risk flags
- Equity dilution from the Rights Issue
- Selling pressure from the Promoter OFS
- Auditor resignation (casual vacancy filled)
Key Highlights
Board approved a two-step scheme involving a Promoter OFS and a Public-only Rights Issue to reach 25.00% public shareholding.
Promoter holding as of June 2026 is 79.84%, necessitating a reduction to 75% for compliance.
Nuvama Wealth Management Limited appointed as the advisor for capital restructuring and MPS execution.
CS Geeta Serwani appointed as Secretarial Auditor for FY 2025-26 to fill a casual vacancy following a resignation.
A dedicated 'MPS Committee' has been formed to oversee the regulatory and operational execution of the restructuring.
👀 What to Watch
Investors should monitor the upcoming announcements regarding the OFS floor price and the Rights Issue ratio/pricing, as these will determine the extent of equity dilution and capital inflow.
Lords Mark Industries to Evaluate MPS Compliance Methods on August 6, 2026
Lords Mark Industries has scheduled a board meeting for August 6, 2026, to address Minimum Public Shareholding (MPS) compliance. With promoter holding currently at 79.84%, the company must reduce this to 75% to meet SEBI norms. The board will evaluate various options including Rights Issues, Offer for Sale (OFS), Bonus Issues, and Qualified Institutions Placement (QIP). Additionally, the meeting will address the appointment of a new Secretarial Auditor following a recent resignation.
Confidence: HIGH
What changedThe company is initiating formal regulatory steps to reduce promoter stake and fill a vacancy in its auditing team.
Why it mattersAchieving the 25% minimum public shareholding is a mandatory regulatory requirement for continued listing; the method chosen will determine the extent of equity dilution for existing shareholders.
Current Promoter Holding: 79.84%Required Public Holding: 25.0%TTM Revenue: Rs 601 CrTTM PAT: Rs 53 CrPrice Return (6-month): -99.3%
📅 Short termExpect volatility leading up to and following the August 6 meeting as the market reacts to the proposed dilution method.
📈 Long termWhile necessary for compliance, the company faces significant structural challenges given the 99% share price collapse and the need to stabilize its corporate governance following an auditor resignation.
⚠ Risk flags
- Equity dilution risk from QIP/OFS
- Auditor resignation (casual vacancy)
- Extreme historical price volatility (-99.3% in 6 months)
- Negative Market Cap reported in context (Rs -205 Cr)
Key Highlights
Board meeting scheduled for August 6, 2026, to discuss regulatory compliance.
Promoter holding stands at 79.84% as of June 2026, requiring a minimum 4.84% reduction to meet the 75% MPS limit.
Multiple capital-raising and dilution tools under consideration: Rights Issue, OFS, Bonus, and QIP.
New Secretarial Auditor to be appointed for FY 2025-26 following a casual vacancy caused by resignation.
Company reported TTM Revenue of Rs 601 Cr and TTM PAT of Rs 53 Cr despite extreme price volatility.
👀 What to Watch
Investors should monitor the August 6 board outcome to identify the specific method chosen for MPS compliance, as an OFS or QIP could lead to immediate equity dilution or price pressure.
Lords Mark Industries Secures L1 Status for Chhattisgarh Solar Project at ₹47,625 Per Unit
Lords Mark Industries has been declared the L1 bidder for a state-wide solar home lighting project by the Chhattisgarh State Renewable Energy Development Agency (CREDA). The contract involves the supply, installation, and commissioning of solar systems with a minimum 300 Wp capacity at a fixed rate of ₹47,625 per unit (excluding GST). The agreement includes a 5-year comprehensive maintenance contract (CMC) valued at ₹3,875 per unit. While the total number of units is not specified, the project covers the entire state of Chhattisgarh, indicating a significant scale for the company's lighting and renewable energy division.
Confidence: MEDIUM
What changedThe company has transitioned from a bidder to the confirmed L1 contractor for a major state government renewable energy project in Chhattisgarh.
Why it mattersThis contract establishes a significant footprint in the renewable energy sector and provides a recurring revenue stream through the 5-year maintenance component.
Unit Rate (excl. GST): ₹47,625Supply Component: ₹42,000CMC Component: ₹3,875Maintenance Period: 5 YearsMinimum Capacity: 300 Wp
📅 Short termThe announcement is likely to be viewed positively by the market as it demonstrates competitive bidding strength and government project wins.
📈 Long termIf executed successfully, this state-wide project could serve as a credential for securing larger renewable energy contracts in other Indian states.
⚠ Risk flags
- Total order volume/quantity not disclosed
- Execution risks across a wide state-level geography
- Dependency on state government payment cycles
Key Highlights
Achieved L1 bidder status for solar home lighting systems across the entire state of Chhattisgarh
Approved unit rate of ₹47,625 excluding GST per system
Includes a 5-year Comprehensive Maintenance Contract (CMC) valued at ₹3,875 per unit
Minimum system capacity requirement set at 300 Wp
Supply of material component valued at ₹42,000 per unit
👀 What to Watch
Investors should monitor for subsequent filings regarding the total quantity of systems ordered to determine the aggregate contract value and its impact on the company's revenue.
10.28 Lakh Shares to be Listed for BCCL at ₹158 Conversion Price
Lords Mark Industries is proceeding with the listing of 1,028,483 equity shares issued to Bennett Coleman and Company Limited (BCCL) following proceedings before the Delhi High Court. The shares are being issued at a conversion price of ₹158 per share, which is significantly higher than the current market price of ₹80.3. This issuance stems from a Share Cum Warrant Subscription Agreement dated August 1, 2023. The company has now initiated the formal application process for listing and trading approval from the BSE.
Confidence: HIGH
What changedThe company has moved from a legal undertaking to the actual regulatory process of listing shares for BCCL at a pre-agreed valuation.
Why it mattersThe ₹158 conversion price provides a significant valuation benchmark from a major institutional investor, which is nearly double the current market price, suggesting long-term confidence despite recent price volatility.
Shares to be issued: 10,28,483Conversion Price: ₹158Current Market Price: ₹80.3Agreement Date: 01 August 2023
📅 Short termThe news is likely to be viewed positively by the market as it confirms institutional participation at a substantial premium to the current price.
📈 Long termThe entry of a high-profile institutional investor like BCCL adds credibility to the company's diversified business strategy across healthcare and energy sectors.
⚠ Risk flags
- Equity dilution for existing shareholders
- Issuance resulted from a legal dispute in the Delhi High Court
Key Highlights
Issuance of 10,28,483 equity shares to Bennett Coleman and Company Limited (BCCL)
Conversion price set at ₹158 per share, approximately 97% higher than the current market price of ₹80.3
Process initiated for listing and trading approval from BSE Limited following a Delhi High Court undertaking
The issuance is based on a Share Cum Warrant Subscription Agreement dated 01 August 2023
👀 What to Watch
Investors should monitor the timeline for BSE listing approval and observe if the high conversion price of ₹158 acts as a support level for market sentiment.
